PROFILPELAJAR.COM

ABT-925

ABT-925
Clinical data
Other namesABT925; A-437203; A437203; BSF-201640; BSF201640; DTA-201; DTA201; LU-201640; LU201640
Routes of
administration		Oral[1][2]
Drug classDopamine D3 receptor antagonist
ATC code
  • None
Identifiers
  • 2-[3-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]propylsulfanyl]-1H-pyrimidin-6-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H27F3N6OS
Molar mass456.53 g·mol−1
3D model (JSmol)
  • CC(C)(C)C1=NC(=CC(=N1)N2CCN(CC2)CCCSC3=NC=CC(=O)N3)C(F)(F)F
  • InChI=1S/C20H27F3N6OS/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30)
  • Key:KXVAICSRMHXLJN-UHFFFAOYSA-N

ABT-925, also known as A-437203 or as LU-201640, is a selective dopamine D3 receptor antagonist which was under development for the treatment of schizophrenia but was never marketed.[1][3][2] It is taken orally.[1][2]

The drug shows affinity for the dopamine D3 receptor and to a much lesser extent for the dopamine D2 receptor, with Ki values of 0.97–3.2 nM and 75 nM, respectively, and with 45- to 120-fold selectivity for the dopamine D3 receptor over the dopamine D2 receptor.[4][5][2] It showed little activity in classical tests of antipsychotic-like activity in rodents, for instance inhibition of methamphetamine-induced hyperlocomotion and inhibition of apomorphine-induced climbing behavior.[5][6] The drug does not produce catalepsy and does not affect prolactin levels in rodents.[5][6] The occupancy of the dopamine D3 receptor by ABT-925 has been studied in humans.[4][7][8]

ABT-925 was first described in the scientific literature by 1997.[5][9][6] At the time, it was the most potent and selective dopamine D3 receptor antagonist yet known.[5] In addition, the drug has been said to have been the first selective dopamine D3 receptor antagonist.[4] It was under development by Abbott Laboratories.[1][3] The drug reached phase 2 clinical trials prior to the discontinuation of its development.[1][3] ABT-925 is known to have been in active phase 2 trials between 2001 and 2007.[1] It failed to show antipsychotic effectiveness in acute schizophrenia in a phase 2 trial published in 2011.[10][4][2]

See also

References

  1. ^ a b c d e f "ABT 925". AdisInsight. 24 January 2013. Retrieved 7 June 2026.
  2. ^ a b c d e Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz DA, Goenjian A, Robieson WZ, et al. (April 2011). "A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia". Journal of Clinical Psychopharmacology. 31 (2): 221–225. doi:10.1097/JCP.0b013e31820e4818. PMID 21346607.
  3. ^ a b c "Delving into the Latest Updates on A-437203 with Synapse". Synapse. 30 May 2026. Retrieved 7 June 2026.
  4. ^ a b c d Gross G, Wicke K, Drescher KU (February 2013). "Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia". Naunyn-Schmiedeberg's Archives of Pharmacology. 386 (2): 155–166. doi:10.1007/s00210-012-0806-3. PMID 23128852.
  5. ^ a b c d e Gross G, Bialojan S, Drescher K, Freeman AS, Garcia-Ladona FJ, Höger T, et al. (1997). "S. 21.02 Evaluation of D3 receptor antagonists". European Neuropsychopharmacology. 7: S120. doi:10.1016/S0924-977X(97)88428-3.
  6. ^ a b c Drescher KU, Garcia-Ladona FJ, Teschendorf HJ, Traut M, Unger L, Wicke KM, et al. (November 2002). In vivo effects of the selective dopamine D3 receptor antagonist A-437203. Abstr.-Soc. Neurosci. Vol. 28.
  7. ^ Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P, et al. (April 2010). "Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925". The International Journal of Neuropsychopharmacology. 13 (3): 273–287. doi:10.1017/S1461145709990642. PMID 19751545.
  8. ^ Day M, Bain E, Marek G, Saltarelli M, Fox GB (April 2010). "D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET". The International Journal of Neuropsychopharmacology. 13 (3): 291–292. doi:10.1017/S1461145710000180. PMID 20196920.
  9. ^ Unger L, Garcia-Ladona F, Wernet W, Sokoloff P, Wicke KM, Gross G (2002). In vitro characterization of the selective dopamine D3 receptor antagonist A-437203. Abstr.-Soc. Neurosci. Vol. 28.
  10. ^ Pich EM, Collo G (September 2015). "Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs". European Neuropsychopharmacology. 25 (9): 1437–1447. doi:10.1016/j.euroneuro.2015.07.012. PMID 26298833.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.